Login / Signup

Gluco-1 H-imidazole: A New Class of Azole-Type β-Glucosidase Inhibitor.

Sybrin P SchröderLiang WuMarta ArtolaThomas HansenWendy A OffenMaria J FerrazKah-Yee LiJohannes M F G AertsGijsbert A van der MarelJeroen D C CodéeGideon J DaviesHerman S Overkleeft
Published in: Journal of the American Chemical Society (2018)
Gluco-azoles competitively inhibit glucosidases by transition-state mimicry and their ability to interact with catalytic acid residues in glucosidase active sites. We noted that no azole-type inhibitors described, to date, possess a protic nitrogen characteristic for 1 H-imidazoles. Here, we present gluco-1 H-imidazole, a gluco-azole bearing a 1 H-imidazole fused to a glucopyranose-configured cyclitol core, and three close analogues as new glucosidase inhibitors. All compounds inhibit human retaining β-glucosidase, GBA1, with the most potent ones inhibiting this enzyme (deficient in Gaucher disease) on a par with glucoimidazole. None inhibit glucosylceramide synthase, cytosolic β-glucosidase GBA2 or α-glucosidase GAA. Structural, physical and computational studies provide first insights into the binding mode of this conceptually new class of retaining β-glucosidase inhibitors.
Keyphrases
  • molecular docking
  • molecular dynamics simulations
  • candida albicans
  • ionic liquid
  • endothelial cells
  • mental health
  • smoking cessation
  • case control